Factors regulating the activity of b-lymphocytes, as potential biomarkers of multiple sclerosis

Sursiakova N.V.; Baĭdina T.V.; Kuklina E.M.; Trushnikova T.N.; Ozhgibesova T.V.

doi:https://doi.org/10.17116/jnevro20191192224

Sursiakova N.V.

Vagner’s Perm State Medical University, Perm, Russia

Baĭdina T.V.

GBOU VPO "Permskaia gosudarstvennaia meditsinskaia akademiia im. akad. E.A. Vagnera", Perm'

Kuklina E.M.

FGBUN "Institut kologii i genetiki mikroorganizmov" Ural'skogo otdeleniia RAN, Perm'

Trushnikova T.N.

GBOU VPO "Permskaia gosudarstvennaia meditsinskaia akademiia im. akad. E.A. Vagnera", Perm'

SPIN RSCI: 6200-1697
Scopus AuthorID: 55843664200
ORCID: 0000-0001-9199-7392

Ozhgibesova T.V.

Vagner’s Perm State Medical University, Perm, Russia

Factors regulating the activity of b-lymphocytes, as potential biomarkers of multiple sclerosis

Authors:

Sursiakova N.V., Baĭdina T.V., Kuklina E.M., Trushnikova T.N., Ozhgibesova T.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(2‑2): 24‑27

DOI: 10.17116/jnevro20191192224

Read: 1691 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Sursiakova NV, Baĭdina TV, Kuklina EM, Trushnikova TN, Ozhgibesova TV. Factors regulating the activity of b-lymphocytes, as potential biomarkers of multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(2‑2):24‑27. (In Russ.)
https://doi.org/10.17116/jnevro20191192224

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))

Использование инфографики авторами научных работ

Close metadata

Abstract:

Objective. To assess the possibility of using serum levels of chemokine CXCL13, B-cell activating factor (BAFF), interleukin 1 and 17 (IL-10, IL-17) as markers of the development/progression of multiple sclerosis (MS). Material and methods. Sixty-seven patients with MS in remission and 14 healthy volunteers were examined. The levels of BAFF, CXCL13 and the main products of Th17 and Treg — interleukin 17 (IL-17) and IL-10 in the serum were determined, their relationship with clinical characteristics of MS during remission was assessed. Results and conclusion. The content of IL-17 and BAFF in the serum of patients with MS did not differ significantly from the control group, and the levels of IL-10 and CXCL13 were lower than the corresponding indicators of healthy donors. In patients with MS, no correlation was found between IL-17, IL-10, BAFF and clinical characteristics of MS. The level of CXCL13 correlated with quality of life, fatigue, clinical and functional status of patients. According to the results of this study, BAFF and CXCL13 cannot be proposed as diagnostic biomarkers of MS.

Keywords:

multiple sclerosis

Th17

B-cells

BAFF

CXCL13

Authors:

Sursiakova N.V.

Vagner’s Perm State Medical University, Perm, Russia

Baĭdina T.V.

GBOU VPO "Permskaia gosudarstvennaia meditsinskaia akademiia im. akad. E.A. Vagnera", Perm'

Kuklina E.M.

FGBUN "Institut kologii i genetiki mikroorganizmov" Ural'skogo otdeleniia RAN, Perm'

Trushnikova T.N.

GBOU VPO "Permskaia gosudarstvennaia meditsinskaia akademiia im. akad. E.A. Vagnera", Perm'

SPIN RSCI: 6200-1697
Scopus AuthorID: 55843664200
ORCID: 0000-0001-9199-7392

Ozhgibesova T.V.

Vagner’s Perm State Medical University, Perm, Russia

Close metadata

References:

Kuklina EM, Baidina TV, Danchenko IYu, Nekrasova IV. Semaforin Sema4D in the Immune System in Multiple Sclerosis. Bull Exp Biol Med. 2014;157(2):234-237. (In Russ.) https://doi.org/10.1007/s10517-014-2533-x
Dobson R, Ramagopalan S, Davis A, Giovannoni G. Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude. Journal of Neurology, Neurosurgery & Psychiatry. 2013;84(8):909-914. https://doi.org/10.1136/jnnp-2012-304695
Duddy M, Niino M, Adatia F, Hebert S, Freedman M, Atkins H, Kim H. J, Bar-Or A. Distinct Effector Cytokine Profiles of Memory and Naive Human B Cell Subsets and Implication in Multiple Sclerosis. The Journal of Immunology. 2007;178(10):6092-6099. https://doi.org/10.4049/jimmunol.178.10.6092
Disanto G, Morahan J, Barnett M, Giovannoni G, Ramagopalan S. The evidence for a role of B cells in multiple sclerosis. Neurology. 2012;78(11):823-832. https://doi.org/10.1212/wnl.0b013e318249f6f0
Ragheb S, Li Y, Simon K, VanHaerents S, Galimberti D, De Riz M, Fenoglio C, Scarpini E, Lisak R. Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid. Multiple Sclerosis Journal. 2011;17(7):819-829. https://doi.org/10.1177/1352458511398887
Mariette X. How does BAFF activate B cells in patients with autoimmune diseases? Arthritis Res Ther. 2012;14(1):106. https://doi.org/10.1186/ar3729
Puthenparampil M, Federle L, Miante S, Zito A, Toffanin E, Ruggero S, Ermani M, Pravato S, Poggiali D, Perini P, Rinaldi F, Gallo P. BAFF Index and CXCL13 levels in the cerebrospinal fluid associate respectively with intrathecal IgG synthesis and cortical atrophy in multiple sclerosis at clinical onset. J Neuroinflammation. 2017;14(1):11. https://doi.org/10.1186/s12974-016-0785-2
Wang H, Wang K, Zhong X, Qiu W, Dai Y, Wu A, Hu X. Cerebrospinal Fluid BAFF and APRIL Levels in Neuromyelitis Optica and Multiple Sclerosis Patients During Relapse. J Clin Immunol. 2012;32(5):1007-1011. https://doi.org/10.1007/s10875-012-9709-9
Zhou X, Xia Z, Lan Q, Wang J, Su W, Han Y, Fan H, Liu Z, Stohl W, Zheng SG. BAFF Promotes Th17 Cells and Aggravates Experimental Autoimmune Encephalomyelitis. PLoS ONE. 2011;6(8):e23629. https://doi.org/10.1371/journal.pone.0023629
Lai Kwan Lam Q, King Hung Ko O, Zheng B, Lu L. Local BAFF gene silencing suppresses Th17-cell generation and ameliorates autoimmune arthritis. Proceedings of the National Academy of Sciences. 2008;105(39):14993-14998. https://doi.org/10.1073/pnas.0806044105
Walters S, Webster K. E., Sutherland A, Gardam S, Groom J, Liuwantara D, Marino E, Thaxton J, Weinberg A, Mackay F, Brink R, Sprent J, Grey ST. Increased CD4+Foxp3+ T Cells in BAFF-Transgenic Mice Suppress T Cell Effector Responses. The Journal of Immunology. 2009;182(2):793-801. https://doi.org/10.4049/jimmunol.182.2.793
Mameli G, Cocco E, Frau J, Arru G, Caggiu E, Marrosu MG, Sechi LA. Serum BAFF levels, Methypredsinolone therapy, Epstein-Barr Virus and Mycobacterium avium subsp. paratuberculosis infection in Multiple Sclerosis patients. Sci Rep. 2016;6(1):29268. https://doi.org/10.1038/srep29268
Kannel K, Alnek K, Vahter L, Gross-Paju K, Uibo R, Kisand K. Changes in Blood B Cell-Activating Factor (BAFF) Levels in Multiple Sclerosis: A Sign of Treatment Outcome. PLoS ONE. 2015;10(11):e0143393. https://doi.org/10.1371/journal.pone.0143393
Edwards KR, Goyal J, Plavina T, Czerkowicz J, Goelz S, Ranger A, Cadavid D, Browning JL. Feasibility of the Use of Combinatorial Chemokine Arrays to Study Blood and CSF in Multiple Sclerosis. PLoS ONE. 2013;8(11): e81007. https://doi.org/10.1371/journal.pone.0081007
Lee-Chang C, Lefranc D, Salleron J, Faveeuw C, Allet C, Vermersch P, Oxombre B, Prin L. Susceptibility to experimental autoimmune encephalomyelitis is associated with altered B-cell subsets distribution and decreased serum BAFF levels. Immunol Lett. 2011;135(1-2):108-117. https://doi.org/10.1016/j.imlet.2010.10.006
Brettschneider J, Czerwoniak A, Senel M, Fang L, Kassubek J, Pinkhardt E, Lauda F, Kapfer T, Jesse S, Lehmensiek V, Ludolph AC, Otto M, Tumani H. The Chemokine CXCL13 Is a Prognostic Marker in Clinically Isolated Syndrome (CIS). PLoS ONE. 2010;5(8):e11986. https://doi.org/10.1371/journal.pone.0011986
Komiyama Y, Nakae S, Matsuki T, Nambu A, Ishigame H, Kakuta S, Sudo K, Iwakura Y. IL-17 Plays an Important Role in the Development of Experimental Autoimmune Encephalomyelitis. The Journal of Immunology. 2006;177(1):566-573. https://doi.org/10.4049/jimmunol.177.1.566